Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

December 24, 2025 — Moderna, Inc. is ending 2025 with the kind of chart action that makes both traders and long-term biotech investors sit up straight. After a sharp multi-day run, Moderna stock pulled back hard: shares closed at about $32.29 on Dec. 23, down ~7.48% on the day, and were indicated around $32.11 in pre-market trading on Dec. 24. StockAnalysis

Biotechnology · NASDAQ:MRNA · Stock Market
Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Moderna, Inc. has just had one of its most dramatic weeks of 2025. Shares plunged early in the week after news that the U.S. Food and Drug Administration may tighten vaccine approval standards, then rebounded sharply on Friday after a massive French real‑world study reaffirmed the safety and effectiveness of its COVID‑19 vaccine. Investopedia+2Investopedia+2
6 December 2025
Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna Inc. enters Sunday, November 23, 2025, as one of the most controversial and heavily shorted stocks in the S&P 500. The biotech is trading near its 52‑week low after the COVID‑vaccine boom faded, yet it’s rolling out a new three‑year strategy, taking on $1.5 billion in debt, cutting pipeline projects and doubling down on its mRNA platform in respiratory disease and cancer. Reuters+3Financial Times+3Barron's+3
23 November 2025
·
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts

Moderna, Inc. drew multiple analyst headlines today as Wall Street recalibrated views in the wake of last week’s earnings and ongoing cost‑cutting. UBS highlighted potential 2026 upside on pipeline and expense discipline; Redburn Atlantic trimmed its price target; and Bernstein reiterated a neutral stance. Shares traded higher during the U.S. session alongside the commentary. MarketScreener+2MarketScreener+2
11 November 2025
··
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

U.S. equities opened in the red Thursday, extending this week’s choppy pattern as investors weighed mixed corporate results against macro headwinds. At the bell, all three major indices slipped, with breadth tilting negative. The tone was cautious amid debate over still‑rich tech multiples and uncertain economic signals. Reuters
6 November 2025
······
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna, Inc. posted third‑quarter 2025 revenue of ~$1.02 billion and a GAAP loss of $0.51 per share, topping Wall Street estimates as sales of its updated COVID‑19 vaccine outperformed. The company narrowed its full‑year revenue range to $1.6–$2.0 billion, cut operating‑expense guidance, and raised its year‑end cash outlook. Shares popped in pre‑market trading before wobbling intraday. SEC+1
6 November 2025
··
Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

On Oct. 30, 2025 Moderna’s stock jumped sharply. Midday trading saw MRNA up ~11.7% to about $27.56tradingview.com, reversing much of September–October’s slide. This followed a STAT News report that Moderna has held buyout or partnership talks with at least one large drugmakertradingview.com. Moderna’s shares had been languishing near all-time lowstradingview.com, so today’s news sparked a relief rally. Even so, with the recent gain the stock remains roughly 37% below its Jan. 2025 pricetradingview.com. Moderna declined to comment on the rumors. A company spokesperson reiterated that Moderna is “confident in our strategy,” highlighting that it has advanced several new products this yeartradingview.com.
30 October 2025
··

Stock Market Today 19.10.2025

ENDEDLive coverage has endedEnded: October 21, 2025, 6:00 AM EDT IonQ vs Nvidia: Which AI Stock Has the Better Long-Term Upside? October 20, 2025, 5:58 AM EDT. IonQ offers long-term AI potential through quantum computing, with room-temperature operation and growing partnerships such as Oak Ridge National Laboratory. Its recent Q3 results showed revenue up 102% YoY to $12.4 million and $63.5 million in new bookings, but the firm remains unprofitable, posting a net loss of $52.5 million as it spends on R&D and pursues growth, including the Qubitekk acquisition to build a networked quantum ecosystem. Nvidia remains the more established
19 October 2025
···········
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s stock is back in the spotlight after a turbulent week of news that sent the Nasdaq-listed shares swinging. On Wednesday, MRNA jumped over 5%, climbing to around $27.7 by market close marketbeat.com. The mini-rally came amid a flurry of developments – from upbeat trial data on a new cancer vaccine to analysts debating whether Moderna’s future is bright or bleak. Even after the pop, however, Moderna’s stock is a shadow of its former self: shares have cratered roughly 80% below last year’s levels marketbeat.com and are down one-third in 2025 alone. The once high-flying biotech – which briefly surpassed $170 billion in market value during the COVID vaccine euphoria – is now hovering near multi-year lows, with a market cap around $10–11 billion ts2.tech.
16 October 2025
··
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna’s stock was a market darling during the pandemic but has suffered a long decline. On Oct 7 2025, the stock closed at $27.34, down roughly 0.7% from $27.54 on the prior sessionstockinvest.us. Technical analysts at Stockinvest.us noted the shares were near the upper part of a wide falling trend and predicted a possible trading range of $26.40–$28.73 on Oct 8, with longer‑term support around $26 and resistance near $31stockinvest.us. While short‑term signals were positive, they cautioned that the overall downward trend remainsstockinvest.us.
8 October 2025
··
Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Nvidia–OpenAI Partnership: Nvidia announced a landmark collaboration with OpenAI to deploy at least 10 gigawatts of AI computing power. Under the plan, Nvidia will invest up to $100 billion as each gigawatt of NVIDIA systems is deployed nvidianews.nvidia.com. The first 1 GW is slated for late 2026 on Nvidia’s new “Vera Rubin” supercomputer. CEO Jensen Huang said this marks “the next leap forward — deploying 10 gigawatts to power the next era of intelligence” nvidianews.nvidia.com. OpenAI’s Sam Altman emphasized that “everything starts with compute,” and the new chips will fuel AI breakthroughs. This deal comes amid massive demand for AI chips – Nvidia will continue to serve all customers, but the investment ties OpenAI and Nvidia closely together nvidianews.nvidia.com nvidianews.nvidia.com.
28 September 2025
·········
1 2 3 4
Follow on Google News
Add as preferred source Open in Google News

US Stock Market Today Updates

MARKET CALENDAR

Key Events Today

The catalysts most likely to move markets.

#1

Warsh at Jackson Hole

Policy tone can move rates, USD, equities, gold and crypto simultaneously.

#2

Michigan sentiment

A weak final reading or elevated inflation expectations could pressure risk assets.

#3

Chicago PMI

A surprise versus 58.0 may alter the near-term manufacturing-growth narrative.

View full calendar
Times and estimates may change. Verify before trading.